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Background: Serotonin (5-HT3) receptor antagonists are a class of antiemetic medications often used to prevent
nausea and vomiting among patients undergoing chemotherapy, radiotherapy or surgery. However, recent studies
suggest that these agents might be associated with increased cardiac harm. To examine this further, we are
proposing to conduct a systematic review and network meta-analysis on the comparative safety of 5-HT3 receptor
antagonists among patients undergoing chemotherapy or surgery.
Methods/Design: Studies reporting one or more safety outcomes of interest for 5-HT3 receptor antagonists
compared with each other, placebo, and/or other anti-emetic agents (for example, benzamides, phenothiazines,
butyrophenones, antihistamines, and anticholinergics) among children and adult patients undergoing surgery or
chemotherapy will be included. Our primary outcome of interest is arrhythmia. Our secondary outcomes include
cardiac death, QT prolongation, PR prolongation, all-cause mortality, nausea, and vomiting. We will include
experimental studies, quasi-experimental studies (namely controlled before-after and interrupted time series), and
observational studies (namely cohort studies). We will not limit inclusion by publication status, time period, duration
of follow-up or language of dissemination.
Electronic databases (for example, MEDLINE, EMBASE) will be searched from inception onwards. These main
searches will be supplemented by searching for difficult to locate and unpublished studies, such as dissertations,
and governmental reports. The eligibility criteria will be pilot-tested and subsequently used to screen the literature
search results by two reviewers in duplicate. A similar process will be followed for full-text screening, data
abstraction, and risk of bias/methodological quality appraisal. The Cochrane Risk of Bias tool will be used to
appraise experimental and quasi-experimental studies, and cohort studies will be assessed using the Newcastle
Ottawa Scale. If the data allows, random effects meta-analysis and a network (that is, mixed treatment comparisons)
meta-analysis will be conducted. All analyses will be conducted separately for different study designs, patient
populations (for example, children and adults), and reason for administering 5-HT3 receptor antagonists (for
example, post-surgery and chemotherapy).
Discussion: Our results will help inform patients, clinicians, and health policy-makers about the potential safety
concerns, as well as the comparative safety, of using these antiemetic agents.
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One of the most distressing symptoms for patients
undergoing both surgery and chemotherapy is nausea
and vomiting [1,2]. Nausea and vomiting has a significant
impact on quality of life [3,4], and can lead to malnutrition
[4], inability to respond to treatment [4], and an increased
length of hospitalization [5]. Among patients undergoing
surgery, postoperative nausea and vomiting has also been
associated with pulmonary complications and wound de-
hiscence [6]. Most patients undergoing chemotherapy ex-
perience nausea and vomiting [7], while the occurrence of
postoperative nausea and vomiting among patients follow-
ing some surgical procedures can be as high as 70% [8].
Serotonin (5-HT3) receptor antagonists were intro-
duced as antiemetic medications, as they inhibit vagal
nerves in the central nervous system and intestinal mu-
cosa that trigger the emetic reflex [9]. First-generation
5-HT3 receptor antagonists include ondansetron (brand
name Zofran), dolasetron (brand names Anzemet,
Anemet), and granisetron (brand names Sancuso, Kytril,
Kevatril). Palonosetron (brand names Aloxi, Alexi) is
a second-generation receptor antagonist [10]. These
agents may be administered orally, subcutaneously,
or intravenously.
Previous systematic reviews have found that 5-HT3
receptor antagonists are effective for postoperative and
chemotherapy-induced nausea and vomiting [7,11-13].
As such, 5-HT3 receptor antagonists are recommended
as the first-line treatment in chemotherapy-induced nau-
sea and vomiting in adults and children [14]. They are
also recommended for those patients undergoing surgery
who are most at risk of postoperative nausea and
vomiting [15,16].
Although 5-HT3 antagonist receptors might effectively
reduce nausea and vomiting, concerns have been raised
that these agents might be associated with cardiac risk.
Some evidence suggest that 5-HT3 antagonist receptors
prolong the QT interval (measured using electrocardio-
gram (ECG)) [17,18], which is associated with an increased
risk of serious ventricular arrhythmias (for example,
torsades de pointes). In vitro studies indicate that 5-HT3
antagonists block voltage-dependent sodium channels and
hERG-potassium channel (cardiac ion channels), yet the
magnitude and type of ECG change may differ for a
particular drug, suggesting that the comparative safety of
these medications is an important factor to examine. This
is especially the case when factors that may impact blood
levels of these agents are also present [19]. This informa-
tion cannot be gleaned from previous systematic reviews
of 5-HT3 receptor antagonists [7,11-13], as cardiac safety
was not fully examined. As such, we are conducting this
systematic review to determine the comparative safety of
5-HT3 receptor antagonists among patients undergoing
chemotherapy or surgery. This research question wasposed by policy makers in Canada to inform their
decision-making related to these agents.
Methods/Design
This is a protocol for a systematic review and network
meta-analysis, which was registered with the PROSPERO
database (CRD42013003564). Our reporting conforms to
guidance put forth by the preferred reporting items for
systematic reviews and meta-analyses protocols (or
PRISMA-P) initiative [20].
Eligibility criteria
We will include studies of adults (aged ≥18 years) and
children undergoing surgery or chemotherapy who are ad-
ministered first-generation and second-generation 5-HT3
antagonist receptors. We will explore the safety of each of
the 5-HT3 antagonists against each other, against placebo,
and/or other antiemetic agents, including benzamides,
phenothiazines, butyrophenones, antihistamines, anticho-
linergics, and neurokin1 (NK1) antagonists. We will in-
clude studies of monotherapy of any dose, formulation,
and duration. We will exclude studies that only include
patients undergoing radiation therapy.
We will limit the systematic review to experimental
studies (randomized clinical trials (RCTs), quasi-RCTs,
non-RCTs), quasi-experimental studies (interrupted time
series, controlled before and after studies), and observa-
tional (cohort) studies. The primary outcome of interest
is arrhythmia. Secondary outcomes include sudden car-
diac death, QT prolongation, PR prolongation, all-cause
mortality, nausea (for example, the number of patients
experiencing nausea or retching), vomiting (for example,
the number of patients experiencing vomiting), and
delirium.
Study inclusion will not be limited by publication sta-
tus, time period, duration of follow-up, or language of
dissemination. Studies will be excluded if they are animal
studies or if there are no quantitative data to abstract (for
example, letters, or commentaries). We will use Google
Translate to determine eligibility and ScienceDocs, Inc.
for translating languages in which the team is not fluent.
A draft eligibility form is presented in Additional file 1 for
both level 1 screening (titles and abstracts) and level 2
screening (potentially relevant full-text articles).
Information sources and literature search
We will search the following electronic databases from
inception onwards using medical subject headings
(MeSH) and text words related to 5-HT3 receptor antag-
onists for nausea and vomiting: MEDLINE, EMBASE,
and the Cochrane Central Register of Controlled Trials.
We will supplement this search by conducting searches
for grey literature (that is, those that are difficult to
locate, or unpublished material) using guidance from the
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[21]. Specifically, we will search public health, drug regu-
latory and trial registry websites (such as, Public Health
Agency of Canada, Health Canada, Food and Drug
Administration (FDA), and Clinical Trials.gov), websites
of organizations that produce guidelines (such as,
CADTH, Centre for Disease Control and Prevention,
World Health Organization (WHO), Agency for Health
Research and Quality, and the National Institute for
Health and Clinical Excellence), trial protocol registries
(such as, the WHO International Clinical Trials Registry
Platform), and conduct general Internet searches in
Google. Literature saturation will be ensured by searching
the authors’ personal files, contacting 5-HT3 manufac-
turers, scanning the reference lists of included studies and
relevant reviews, forward citation searching using Google,
Scopus and Web of Science, and contacting experts in the
field (such as, clinicians, and researchers).
All literature searches will be conducted by an experi-
enced librarian. The main search strategy (MEDLINE)
will be peer-reviewed by another librarian using Peer
Review of Electronic Search Strategies (PRESS) [22]. The
draft literature search for the main search strategy can
be found in Additional file 1.
Study selection process
To ensure high inter-rater reliability, a training exercise
will be conducted prior to commencing screening. Using
the predefined inclusion and exclusion criteria outlined
in Additional file 1, a random sample of 50 titles and
abstracts (citations) from the literature search will be
screened by the systematic review team. We will calcu-
late inter-rater agreement for study inclusion using the
kappa statistic [23]. If poor-to-moderate agreement is
observed (that is, kappa statistic ≤0.6), the eligibility
criteria will be revised, as necessary. Subsequently, each
citation will be screened by two reviewers in duplicate.
Conflicts will be resolved by team discussion. A similar
process will be followed for screening potentially relevant
full-text articles. All levels of screening will be conducted
using our online SysRev Tool, proprietary software devel-
oped by members of our group at the Li Ka Shing Know-
ledge Institute of St Michael’s Hospital [24].
Data items and data collection process
We will abstract data on study characteristics (for ex-
ample, study design, year of study conduct, sample size,
setting, country of study conduct, intervention and com-
parator), participant characteristics (for example, num-
ber of patients, mean age and standard deviation, type
and duration of chemotherapy, type of cancer, type and
duration of surgery, type of anesthesia, history of previous
conduction abnormality, use of diuretics, steroids or anti-
arhythmics, co-morbidities, and metabolic abnormalities),and outcome results (for example, arrhythmia, and QT
prolongation) for the following time points: 6, 12, and 24
months, as well as the longest duration of follow-up. Spe-
cific details on the interventions will be abstracted, includ-
ing type of 5-HT3 receptor antagonist, dose, duration of
use, cumulative dose and formulation.
Prior to commencing data abstraction, we will pilot-
test a draft data abstraction form using a random sample
of 10 included studies. When at least moderate agree-
ment is observed (that is, kappa statistic ≤0.6), the data
will be abstracted in duplicate by two reviewers. We will
ensure that data are not counted twice by sorting
through major publications and their respective com-
panion reports, which include data from the same study
group.
Methodological quality/risk of bias appraisal
We will appraise the risk of bias of RCTs, quasi-RCTs,
non-RCTs, interrupted time series, and controlled
before-after studies using the Cochrane Effective Prac-
tice and Organisation of Care Risk of Bias Tool [25]. We
will appraise the methodological quality of cohort studies
using the Newcastle-Ottawa Scale [26]. Specific to studies
reporting harms, the McHarm quality rating tool will be
used [27]. We will assess for publication bias using funnel
plots [28].
Synthesis of included studies
We will first describe our systematic review results by
reporting study characteristics, patient characteristics,
risk of bias/methodological quality results, and frequen-
cies of outcomes across the included studies. It is antici-
pated that we will have sufficient data to calculate
pooled estimates of effects, which will be derived using a
random-effects model [29]. We will ensure that the 95%
confidence intervals can be derived using a normal dis-
tribution. Separate meta-analyses will be conducted by
age category (that is, children versus adults) and patient
population (that is, surgery versus chemotherapy).
Prior to conducting the meta-analysis, we will assess
for three different types of heterogeneity: 1) clinical, 2)
methodological, and 3) statistical heterogeneity. Clinical
heterogeneity will be judged based on the clinical insight
of the team. Similarly, methodological heterogeneity will
be assessed by examining the included study characteris-
tics and using our methodological judgment. Statistical
heterogeneity will first be assessed by visually inspecting
the forest plots. Subsequently, we will quantitatively assess
heterogeneity using the I2 statistic [30]. A meta-regression
analysis will be considered if at least 10 studies are avail-
able [31] and extensive heterogeneity is identified (for
example, I2 statistic ≥60%) [30]. The meta-regression
analysis will explore the influence of important factors,
including children aged <3 years versus ≥3 years (as the
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tive nausea); type of chemotherapy (for example, use of
cardiotoxic chemotherapy); type of anesthesia (for ex-
ample, use of volatile anesthetics such as sevoflurane
and isoflurane); type of surgery (for example, abdominal
versus thoracic); use of steroids (for example, dexametha-
sone), diuretics, or anti-arrhythmics; history of conduction
abnormality; and presence of metabolic abnormality (for
example, hypo/hyperkalemia, hypo/hypercalcemia) on the
meta-analysis results. These analyses will be conducted
using SAS Version 9.2 [32].
Missing data (for example, measures of variance, such
as standard deviations and standard errors) will be im-
puted using established methods [33].The influence of
our imputations will be examined through a sensitivity
analysis [34]. This approach entails imputing missing
data under a missing-at-random assumption, and then
reweights the imputed data to allow for examining the
missing data under a nonrandom selection.
We anticipate that the data will allow us to conduct a
network (that is, mixed treatment comparisons) meta-
analysis, and our above-described explorations of hetero-
geneity will be helpful in assessing the key assumptions of
homogeneity and similarity. The network meta- analysis,
to be conducted in WinBUGS [35], will allow us to rank
the effectiveness and safety of the different 5-HT3 medica-
tions [36]. Median rankings will be used as point estimates
of the safety for 5-HT3 receptor antagonists. The network
meta-analysis will be conducted using a random effects
model including both direct and indirect treatment
comparisons [36], as well as data from experimental,
quasi-experimental, and cohort studies. To reflect the
uncertainty of summary estimates, 95% credible inter-
vals (CIs) will be calculated using the 2.5 and 97.5 per-
centiles obtained via Monte Carlo simulation of 100,000
iterations. These will be interpreted in the same manner
as the 95% confidence intervals usually obtained
through meta-analysis [36]. Model convergence will be
assessed by examining trace and history plots, as well as
by calculating the Gelman Rubin statistic [37]. The
consistency of our results will be conducted by comparing
our frequentist meta-analysis results to those obtained via
network meta-analysis. This will also be assessed statisti-
cally, using node-splitting and back-calculation statistical
methods [38,39].
Finally, we will conduct multiple sensitivity analyses to
ensure that our results are robust. We will examine the
impact of studies with high risk of bias/methodological
quality, studies with high attrition rates, average adherence
between groups, timing of receipt of the 5-HT3 antagon-
ist, usage and formulation of the antiemetic, inclusion of
quasi-experimental and observational studies in the ana-
lyses, as well as different priors for variance parameters
included in the Bayesian meta-analysis [36].Discussion
This is the first systematic review that we are aware of
to specifically focus on the cardiac safety of 5-HT3 re-
ceptor antagonists for postoperative and chemotherapy-
induced nausea and vomiting, which includes study
designs above and beyond RCTs. Due to the safety con-
cerns of these agents, regulatory actions have been
taken. For example, dolasetron is contraindicated for any
use in children and for postoperative nausea and
vomiting in adults in Canada. If 5-HT3 receptor antago-
nists truly are associated with a prolonged QT interval,
and if this association is a class effect (that is, the risk of
an adverse event is similar across all 5-HT3 antagonists),
it could lead to limitations in use of these agents in
adults and children. Alternatively, it could lead to a need
for regular ECG monitoring of the patients who use
these agents, which would inflict cost to the system and
burden to the patients. Our systematic review will provide
answers to these pertinent issues at hand.
We have developed a multi-faceted, knowledge trans-
lation strategy, which will be tailored to the relevant end
users and will be finalized once the results are available.
Our strategy may include presenting our findings at
relevant conferences (for example, American Association
for Cancer Research), and publishing our results in open
access journals. We will also compile executive summar-
ies tailored to stakeholder groups, such as clinicians and
policy-makers. We will disseminate our results through
newsletters of interested organizations, such as the Drug
Safety and Effectiveness Network in Canada, and the
Canadian Cancer Society. We will also convene dissemin-
ation dialogues with key stakeholders, including policy-
makers, patients, and clinicians. Lastly, we will target
social/mass media, to enhance mainstream uptake.
Additional file
Additional file 1: Appendix.
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